GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Trinity Biotech PLC (NAS:TRIB) » Definitions » Earnings per Share (Diluted)

TRIB (Trinity Biotech) Earnings per Share (Diluted) : $-2.28 (TTM As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Earnings per Share (Diluted)?

Trinity Biotech's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.46. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.28.

Trinity Biotech's EPS (Basic) for the three months ended in Sep. 2024 was $-0.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.28.

Trinity Biotech's EPS without NRI for the three months ended in Sep. 2024 was $-0.43. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.15.

During the past 13 years, Trinity Biotech's highest 3-Year average EPS without NRI Growth Rate was 43.40% per year. The lowest was -57.80% per year. And the median was -8.50% per year.


Trinity Biotech Earnings per Share (Diluted) Historical Data

The historical data trend for Trinity Biotech's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Earnings per Share (Diluted) Chart

Trinity Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.00 -1.60 0.20 -6.00 -3.20

Trinity Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.72 -0.37 -0.73 -0.46

Competitive Comparison of Trinity Biotech's Earnings per Share (Diluted)

For the Medical Devices subindustry, Trinity Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's PE Ratio falls into.



Trinity Biotech Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Trinity Biotech's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-24.018-0)/8.901
=-2.70

Trinity Biotech's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-4.759-0)/10.387
=-0.46

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Trinity Biotech  (NAS:TRIB) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Trinity Biotech Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech Business Description

Traded in Other Exchanges
N/A
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.